NL-OMON41527已完成2 期
Towards patient tailored cancer treatment supported by molecular imaging IMPACT: IMaging PAtients for Cancer drug selecTion - Metastatic Breast Cancer - IMPACT breast
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Patient with first presentation of MBC, regardless of ER and HER2 status of the primary tumor, who is eligible for first-line systemic therapy.
- •- Patient with non-rapidly progressive MBC, not requiring urgent initiation of chemotherapy, based on clinician's evaluation
- •- Patients in whom standard imaging work-up of MBC was recently (<= 28 days) performed
- •- Patient with measurable or clinically evaluable (bone only) disease on recent standard work up of MBC are eligible.
- •- Metastatic lesion(s) of which a histological biopsy can safely be obtained according to standard clinical care procedures.
- •- Performance score 0-2
排除标准
- •- Contraindications for systemic treatment (as will be assigned based on biopsy and experimental scan results), either chemotherapy, hormonal therapy or anti-HER2 therapy, based on clinical judgment of treating medical oncologist and patient history.
- •- Pregnant or lactating women.
- •- Rapidly progressive (visceral) disease requiring rapid initiation of chemotherapy.
研究者
相似试验
进行中（未招募）
不适用
Imaging patients for cancer drug selection - metastatic breast cancerMetastatic Breast CancerEUCTR2013-000551-41-NLniversity Medical Center Groningen
招募中
不适用
Developing personalized cancer therapy strategy through genomic analysis in liquid biopsy and cancer tissue from metastatic gastrointestinal cancer patientsNeoplasmsKCT0003511Pusan National University Hospital210
招募中
不适用
POINTING: Towards patient-tailored cancer immunotherapy supported by a multifaceted predictive signature composed of integrative omics and molecular imaging.NSCLCskin cancer (melanoma)10027476NL-OMON51740niversitair Medisch Centrum Groningen200
已完成
不适用
utritional therapy for cancer patientCTRI/2021/03/031634Rajiv Gandhi university of Health Sciences Grant in aid for advanced research project100
进行中（未招募）
1 期
The BARCODE 2 Study – The Use of Genetic Profiling to Guide Prostate Cancer TreatmentMedDRA version: 19.0Level: PTClassification code 10062904Term: Hormone-refractory prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Prostate CancerEUCTR2016-000869-23-GBThe Institute of Cancer Research